Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ART outcomes in women with adenomyosis by stimulation protocol and dienogest pretreatment
2021-005005-28Phase 4Active
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico
- Start
- Jan 2022
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dienogest, leuprolide, cetrorelix, ganirelix and human chorionic gonadotropin in adenomyosis, endometriosis and infertility (2 arms), sponsored by Azienda Ospedaliera Universitaria Policlinico. Primary endpoint: Live birth after ART. Started Jan 2022; status: active.
02
Drugs
dienogestleuprolidecetrorelixganirelixhuman chorionic gonadotropin
03
Conditions
adenomyosisendometriosisinfertility
Beyond the preview
Go deeper on 2021-005005-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005005-28.